All In Biotech

Drug Trial Radar · NCT06273553

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

An Open-Label, Phase 1/2 Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of RG002 Injection (an mRNA Therapeutic Vaccine) in Subjects With Human Papillomavirus (HPV) 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)

Last checked: Nov 19, 2026Latest source record: Feb 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Mar 2024

Primary completion

Oct 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

Conditions

  • Human Papillomavirus Associated Intraepithelial Neoplasia
  • Cervical Intraepithelial Neoplasia Grade 2/3
  • Human Papillomavirus Type 16 Infection
  • Human Papillomavirus Type 18 Infection

Interventions

  • RG002 injectionBiological

    In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability of RG002 Injection, measured by the incidence of adverse eventsTime frame: Week 9
  2. Part A: Maximum tolerated dose (MTD) and/or RP2D of RG002 InjectionTime frame: MTD:Week 9; RP2D: Week 36
  3. Part B: Primary efficacy of RG002 Injection, measured by the proportion of subjects with histopathological regressionTime frame: Week36

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.